Archive: 08/08/2022
Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with NSCLC
Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with ...
Aug 8, 2022